InvestorsHub Logo
Followers 16
Posts 133
Boards Moderated 0
Alias Born 12/05/2005

Re: pgsd post# 552481

Friday, 12/23/2022 5:35:16 PM

Friday, December 23, 2022 5:35:16 PM

Post# of 703844
AF says the rebuttal to JAMA is peer-reviewed - that is false, correct?

Another area of this rebuttal article that bears scrutiny. "And what about that presumed ‘noteworthy tails of long-term survival curves’? In the DCVax-L group 15.7% of patients were alive 48 months after randomization, whereas in the pivotal EORTC trial on chemo-irradiation with temozolomide without the stringent favorable prognosis patient selection and patients randomized prior to the start of radiotherapy, this was 12.1%."

www.nejm.org/doi/full/10.1056/nejmoa043330
If you look a the KM curves in the Stupp NEJM you notice that there are 4 in the "number at risk" at 36 months in the treatment group (radiation + temozolomide), so I'm thinking that 12% was a KM curve estimate. Subsequent studies casts doubt as well.

www.ncbi.nlm.nih.gov/pmc/articles/PMC7348058/#B1
In this publication of Stupp after a decade, they refer to the original result as 10%, not 12%, and show that subsequent studies have shown nowhere near that -- more like 2%.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News